US Bancorp DE Has $408,000 Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

US Bancorp DE decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 29.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,987 shares of the company’s stock after selling 2,055 shares during the quarter. US Bancorp DE’s holdings in Vaxcyte were worth $408,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of PCVX. Proficio Capital Partners LLC bought a new stake in shares of Vaxcyte during the 4th quarter worth $2,915,000. New York Life Investment Management LLC lifted its position in Vaxcyte by 4.1% in the 4th quarter. New York Life Investment Management LLC now owns 12,469 shares of the company’s stock worth $1,021,000 after buying an additional 494 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in Vaxcyte in the fourth quarter valued at approximately $28,000. Bank of New York Mellon Corp lifted its position in Vaxcyte by 2.4% in the fourth quarter. Bank of New York Mellon Corp now owns 421,938 shares of the company’s stock valued at $34,540,000 after purchasing an additional 9,888 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its position in Vaxcyte by 16.2% in the fourth quarter. Handelsbanken Fonder AB now owns 31,500 shares of the company’s stock valued at $2,579,000 after purchasing an additional 4,400 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group started coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research note on Wednesday. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $147.50.

Insider Buying and Selling

In other news, Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total value of $669,280.00. Following the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,208,443.70. This trade represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,250 shares of company stock worth $4,550,258 in the last three months. 3.10% of the stock is owned by insiders.

Vaxcyte Price Performance

NASDAQ:PCVX opened at $73.24 on Thursday. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The stock’s 50 day simple moving average is $82.65 and its two-hundred day simple moving average is $94.44. The company has a market cap of $9.43 billion, a price-to-earnings ratio of -15.92 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.